The firm identified upcoming data readouts expected by year-end 2025, including HARMONi-2 overall survival and HARMONi-6 squamous non-small cell lung cancer results, as potentially transformative events that could "reset the PD-1 landscape" and drive Summit's stock price beyond previous highs. For deeper insights into SMMT's financial health, valuation metrics, and additional analyst perspectives, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US equities with detailed analysis and actionable intelligence. In other recent news, Summit Therapeutics has been in the spotlight due to its clinical trials and analyst ratings. The company presented longer-term follow-up data from its global Phase 3 HARMONi trial at the World Conference on Lung Cancer, which evaluated the combination of ivonescimab and chemotherapy in treating certain lung cancer patients.